A61P 25 - Drugs for disorders of the nervous system

Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
05/2011
05/12/2011	US20110112097 Substituted imidazoline-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof
05/12/2011	US20110112095 1-aryl-3-aminoalkoxy pyrazoles as sigma ligands enhancing analgesic effect of opioids and attenuating the dependency thereof
05/12/2011	US20110112093 Pyrimidinyl-piperazines useful as d3/d2 receptor ligands
05/12/2011	US20110112092 Aminoquinoline derivatives and their use as adenosine a3 ligands
05/12/2011	US20110112091 Derivatives of tetrabromobenzimidazole, a process for the preparation thereof, a pharmaceutical composition comprising the same, a methof of using the same, a method for modulating or regulating serine/threonine kinases, and serine/threonine kinases modulating agent
05/12/2011	US20110112088 Pyrazoles for the treatment of obesity and other cns disorders
05/12/2011	US20110112083 Fxa inhibitors with cyclic amidoxime or cyclic amidrazone as p4 subunit, processes for their preparations, and pharmaceutical compositions and derivatives thereof
05/12/2011	US20110112082 Cyclic carbazate and semicarbazide inhibitors of 11beta-hydroxysteroid dehydrogenase 1
05/12/2011	US20110112080 Oxazoline derivatives
05/12/2011	US20110112079 Phosphodiesterase inhibitors
05/12/2011	US20110112078 Novel oxadiazolyl-diazabicyclononane derivatives and their medical use
05/12/2011	US20110112077 Quinolizidinone m1 Receptor Positive Allosteric Modulators
05/12/2011	US20110112073 Compositions and methods relating to heat shock transcription factor activating compounds and targets thereof
05/12/2011	US20110112072 Thiophenyl and pyrrolyl azepines as serotonin 5-ht2c receptor ligands and uses thereof
05/12/2011	US20110112071 Novel heterocyclidene acetamide derivative
05/12/2011	US20110112065 Modulators of dopamine neurotransmission
05/12/2011	US20110112064 Pyridyl Amide T-Type Calcium Channel Antagonists
05/12/2011	US20110112058 Novel modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer
05/12/2011	US20110112054 Organophosphorous Compounds for the Activation of Gamma/Delta T Cells
05/12/2011	US20110112053 Pharmacological targeting of vascular malformations
05/12/2011	US20110112050 Separation of polysaccharides by charge density gradient
05/12/2011	US20110112049 Methods of preventing or treating diseases and conditions using complex carbohydrates
05/12/2011	US20110112048 Use of beta-glucan on upper respiratory tract infection symptoms and psychological well-being
05/12/2011	US20110112043 Method of utilizing physiological activity of rare saccharide and composition containing rare saccharide
05/12/2011	US20110112035 Therapeutic use of a growth factor, metrnl
05/12/2011	US20110112034 Modulation of synaptogenesis
05/12/2011	US20110112033 Cognitive enhancement and cognitive therapy using glycyl-l-2-methylprolyl-l-glutamic acid
05/12/2011	US20110112032 Regulation of Brain Natriuretic Peptide and Catecholamines for the Treatment of Cardiovascular Diseases
05/12/2011	US20110112018 Method for the Treatment and/or Prophylaxis of Multiple Sclerosis, and Use of Erythropoietin for the Manufacture of a Medicament for the Intermittent and/or Intermittent Prophylaxis of Multiple Sclerosis
05/12/2011	US20110112016 Compositions and methods for modulating the immune system
05/12/2011	US20110112010 Octanoic acid formulations and methods of treatment using the same
05/12/2011	US20110111528 Modified polypeptides stabilized in a desired conformation and methods for producing same
05/12/2011	US20110111493 Compositions and Methods For Inhibiting Expression Of A Target Gene
05/12/2011	US20110111074 medicine to treat drug addiction and preparation method thereof
05/12/2011	US20110111072 Methods for preventing and treating neurodegenerative diseases
05/12/2011	US20110111070 Use of phy906 as treatment for inflammatory bowel disease and/or irritable bowel syndrome
05/12/2011	US20110111068 Inhibitors of cognitive decline
05/12/2011	US20110111062 Levodopa prodrug mesylate, compositions thereof, and uses thereof
05/12/2011	US20110111051 Prophylactic or alleviating agent for peripheral nerve disorder induced by anti-cancer agent
05/12/2011	US20110111042 Self-microemulsifying systems incorporated into liquid core microcapsules
05/12/2011	US20110111040 Polyelectrolyte-encapsulated gold nanoparticles capable of crossing blood-brain barrier
05/12/2011	US20110111033 Hydrogel with covalently crosslinked core
05/12/2011	US20110111029 Composition for transdermal delivery of cationic active agents
05/12/2011	US20110111027 Immediate release formulations and dosage forms of gamma-hydroxybutyrate
05/12/2011	US20110111025 High Drug Load Formulations and Dosage Forms
05/12/2011	US20110111024 Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
05/12/2011	US20110111014 Methods and compositions for treatment of neurological disorders
05/12/2011	US20110111013 Transdermal therapeutic system for administration of fentanyl or an analogue thereof
05/12/2011	US20110111011 Sublingual apomorphine
05/12/2011	US20110110957 Phenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as bace-1 inhibitors, compositions, and their use
05/12/2011	US20110110955 Antibody cancer immunotherapy
05/12/2011	US20110110948 Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors
05/12/2011	US20110110946 Soluble receptor br43x2 and methods of using
05/12/2011	US20110110943 Soluble receptor br43x2 and methods of using
05/12/2011	US20110110942 Method of promoting dendritic spine density
05/12/2011	US20110110938 Compositions and methods for the treatment of immune related diseases
05/12/2011	US20110110935 Methods and Compositions for Increasing Iduronate 2-Sulfatase Activity in the CNS
05/12/2011	US20110110928 Fc variants with altered binding to fcrn
05/12/2011	US20110110927 Thiophenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as bace-1 inhibitors, compositions, and their use
05/12/2011	US20110110919 Mixture of peptide-bound tryptophan and polypeptide-bound tryptophan
05/12/2011	US20110110913 Pharmaceutical formulations of resveratrol and methods of use thereof for treating cell disorders
05/12/2011	US20110110909 Human facilitating cells
05/12/2011	US20110110908 Treatment of disease conditions via administration of dna repair enzyme
05/12/2011	US20110110901 Methods of long-term culture of eukaryotic cells and uses thereof
05/12/2011	US20110110899 Combined Chemical and Genetic Approaches for Generation of Induced Pluripotent Stem Cells
05/12/2011	US20110110880 Nicotine lozenge compositions
05/12/2011	US20110110868 Functionalized Magnetic Nanoparticles and Methods of Use Thereof
05/12/2011	US20110110861 Methods of Detecting Cells with a Disrupted Cell Membrane, Cells Infected with A Pathogen, Dying Cells or Dead Cells
05/12/2011	US20110110855 Novel ghrelin analogues
05/12/2011	CA2789236A1 Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
05/12/2011	CA2781322A1 Use of danshensu, notoginsenoside r1 or their combination in preparation of medicaments for preventing and treating diseases caused by microcirculation disorder
05/12/2011	CA2780205A1 Methods of treating elevations in mtor signaling
05/12/2011	CA2780128A1 Aryl and heteroaryl sulfones as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
05/12/2011	CA2780040A1 4r,5s-enantiomer of 2-(5-methyl-2-oxo-4-phenyl-pyrrolidin-1-yl)-acetamide with nootropic activity
05/12/2011	CA2779457A1 Methods for treating attention-deficit/hyperactivity disorder
05/12/2011	CA2779442A1 Methods for treating fibromyalgia syndrome
05/12/2011	CA2779070A1 New therapeutic approaches for treating alzheimer disease
05/12/2011	CA2778825A1 Treatment of sunburn using analgesics and antihistamines
05/12/2011	CA2778234A1 Methods and compositions for modulating tau levels
05/11/2011	EP2319936A2 Yeast screens for agents affecting protein folding
05/11/2011	EP2319870A2 Human antibodies that bind human IL-12 and methods for producing
05/11/2011	EP2319867A1 Human monoclonal nicotine specific antibodies
05/11/2011	EP2319847A2 Diazabenzo[de]anthracen-3-one compounds and methods for inhibiting PARP
05/11/2011	EP2319838A1 Therapeutic Molecules and Methods-1
05/11/2011	EP2319826A1 Succinate salt of O-desmethyl-venlafaxin
05/11/2011	EP2319574A2 Drug delivery system for conscious sedation
05/11/2011	EP2319540A1 Sustained release pharmaceutical compounds to prevent abuse of controlled substances
05/11/2011	EP2319523A1 Serine protease inhibitors
05/11/2011	EP2319518A1 Use of CO-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases
05/11/2011	EP2319512A1 Novel 2-amino benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels.
05/11/2011	EP2319511A2 Selective subtype alpha 2 adrenergic agents and methods for use thereof
05/11/2011	EP2319508A1 Use of medium chain triglycerides for the treatment and prevention of Alzheimer's disease and other diseases resulting from reduced neuronal metabolism
05/11/2011	EP2319496A1 Pharmaceutical preparation containing oxycodone and naloxone
05/11/2011	EP2318442A1 Treatment of autoimmune and inflammatory disease
05/11/2011	EP2318441A2 Use of cd95 inhibitors for the treatment of inflammatory disorders
05/11/2011	EP2318437A2 Method for treating multiple sclerosis patients with anti-il2r antibodies
05/11/2011	EP2318416A1 Spiroaminodihydrothiazine derivatives
05/11/2011	EP2318415A1 Oxazolopyrimidines as edg-1 receptor agonists
05/11/2011	EP2318397A2 Substituted indole sulfonamide compounds, their preparation and use as medicaments
05/11/2011	EP2318394A1 Novel phenylimidazole derivatives as pde10a enzyme inhibitors

1 ... 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 ... 1833